|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
1998-4-21
|
|
pubmed:abstractText |
The use of peripheral blood progenitor cells (PBPCs) instead of autologous bone marrow leads to more rapid engraftment following high-dose chemotherapy. Mobilization regimens differ with respect to toxicity, efficiency, and cost.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0041-1132
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
38
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
209-15
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:9531956-Adult,
pubmed-meshheading:9531956-Antineoplastic Agents, Alkylating,
pubmed-meshheading:9531956-Breast Neoplasms,
pubmed-meshheading:9531956-Colony-Stimulating Factors,
pubmed-meshheading:9531956-Cost-Benefit Analysis,
pubmed-meshheading:9531956-Cyclophosphamide,
pubmed-meshheading:9531956-Female,
pubmed-meshheading:9531956-Granulocyte Colony-Stimulating Factor,
pubmed-meshheading:9531956-Hematopoietic Stem Cell Mobilization,
pubmed-meshheading:9531956-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:9531956-Humans,
pubmed-meshheading:9531956-Middle Aged
|
|
pubmed:year |
1998
|
|
pubmed:articleTitle |
A combination of low-dose cyclophosphamide and colony-stimulating factors is more cost-effective than granulocyte-colony-stimulating factors alone in mobilizing peripheral blood stem and progenitor cells.
|
|
pubmed:affiliation |
Division of Hematology and Oncology, Scripps Clinic and Research Foundation, La Jolla, California, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
